MRTX - Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

9393 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858-332-3410
http://www.mirati.com

Settore: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 111

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Charles M. Baum	Pres, CEO & Director	1,01M	N/D	1958
Dr. James G. Christensen	Chief Scientific Officer & Exec. VP	655k	N/D	1968
Dr. Isan Chen	Exec. VP and Chief Medical & Devel. Officer	652,15k	N/D	1962
Mr. Jamie A. Donadio	Consultant	563,35k	N/D	1975
Mr. Daniel R. Faga	Exec. VP, COO & Principal Financial Officer	N/D	N/D	1980

Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a Clinical Collaboration Agreement with Novartis International AG. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 5 dicembre 2019 è 6. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 7; diritti degli azionisti: 4; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.